Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Just Phase 2 results - 35 patients
View:
Post by Eoganacht on May 25, 2022 1:14pm

Just Phase 2 results - 35 patients

I rejigged the latest data (April 29) a little bit. I'm not sure if an Excel cut and paste will work but I'll give it a try. I took just the 35 patients from the phase 2 trial, eliminating 2 CR's (patients 5 & 6 from phase 1) and 1 NR (patient 4 from phase 1) I think things are looking pretty good. There is still a possible CR rate of 63% at 450 days. It all depends on the 450 day assessments of the 17 pending patients (plus a favourable ruling on the 2 PR patients).

Assessment Patient Assessment Visit
90 180 270 360 450
Complete Response ("CR") 15 (42.8%) 12 (34.3%) 7 (20.0%) 3 (8.6%) 3 (8.6%)
Partial Response ("PR") 6 6 2 3 2
Pending 3 8 15 17 17
No Response ("NR") 11 9 11 12 13
CR (Evaluable Patients) 46.90% 44.40% 35% 16.70% 16.70%
CR Potential 68.60% 74.30% 68.60% 65.70% 62.80%
Patients Treated 35 35 35 35 35
Comment by Rumpl3StiltSkin on May 25, 2022 2:21pm
And this is still including the non-optimized first dozen patients? Right? So I think the market will take that into consideration, also. In time. 
Comment by Eoganacht on May 25, 2022 2:38pm
Right!
Comment by Pandora on May 25, 2022 2:22pm
Eoganacht I wonder if you can give some discussion re the NR category. 13 out of 35 is a 37% rating. How does this compare to others, or to expectations. I do not recall what the number of NR's there were in the 6 patients of Phase 1b. Is there any particular factor(s) that you have derived which might be behind this incidence of "no response". I know the CR is the critical ...more  
Comment by Eoganacht on May 25, 2022 2:38pm
Hi Pandora - I think the majority of the NR patients are the first 12 undertreated patients.
Comment by Pandora on May 25, 2022 2:44pm
Thanks Eoganacht -- haven't noticed if that is a clarifying point that is included in the reports. We'll have to see how the next report comes out. In my opinion it would be a positive to clarify it as opposed to having people just see 37% NR.
Comment by ScienceFirst on May 25, 2022 3:28pm
Eoganacht ... What your CR potential numbers show is not only high numbers (60%-75%), despite 12 underdosed patients, but also quite consistent efficacy numbers, no matter the category (90, 180, 270, 360, 450).   And this consistency confirms that our technology destroys instantly, instead of just shrinking the tumors.  This is huge!
Comment by BlueFranky on May 25, 2022 4:22pm
Science, that might be your most compelling post yet!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250